200 related articles for article (PubMed ID: 31313075)
1. Cysteinyl leukotriene receptor type 1 antagonist montelukast protects against injury of blood-brain barrier.
Zhou L; Sun X; Shi Y; Liu J; Luan G; Yang Y
Inflammopharmacology; 2019 Oct; 27(5):933-940. PubMed ID: 31313075
[TBL] [Abstract][Full Text] [Related]
2. HAMI 3379, a CysLT2 receptor antagonist, attenuates ischemia-like neuronal injury by inhibiting microglial activation.
Zhang XY; Wang XR; Xu DM; Yu SY; Shi QJ; Zhang LH; Chen L; Fang SH; Lu YB; Zhang WP; Wei EQ
J Pharmacol Exp Ther; 2013 Aug; 346(2):328-41. PubMed ID: 23750020
[TBL] [Abstract][Full Text] [Related]
3. Montelukast, a Cysteinyl Leukotriene Receptor 1 Antagonist, Induces M2 Macrophage Polarization and Inhibits Murine Aortic Aneurysm Formation.
Kawai Y; Narita Y; Yamawaki-Ogata A; Usui A; Komori K
Biomed Res Int; 2019; 2019():9104680. PubMed ID: 31263710
[TBL] [Abstract][Full Text] [Related]
4. Cysteinyl leukotriene receptor (CysLT) antagonists decrease pentylenetetrazol-induced seizures and blood-brain barrier dysfunction.
Lenz QF; Arroyo DS; Temp FR; Poersch AB; Masson CJ; Jesse AC; Marafiga JR; Reschke CR; Iribarren P; Mello CF
Neuroscience; 2014 Sep; 277():859-71. PubMed ID: 25090924
[TBL] [Abstract][Full Text] [Related]
5. Mechanisms underlying the protective effect of leukotriene receptor antagonist montelukast against doxorubicin induced testicular injury in rats.
Mohamed MZ; Zenhom NM
Prostaglandins Other Lipid Mediat; 2020 Aug; 149():106447. PubMed ID: 32173485
[TBL] [Abstract][Full Text] [Related]
6. Montelukast, a cysteinyl leukotriene receptor-1 antagonist, dose- and time-dependently protects against focal cerebral ischemia in mice.
Yu GL; Wei EQ; Zhang SH; Xu HM; Chu LS; Zhang WP; Zhang Q; Chen Z; Mei RH; Zhao MH
Pharmacology; 2005 Jan; 73(1):31-40. PubMed ID: 15452361
[TBL] [Abstract][Full Text] [Related]
7. Effects of montelukast, a cysteinyl-leukotriene type 1 receptor antagonist, on the pathogenesis of bleomycin-induced pulmonary fibrosis in mice.
Shimbori C; Shiota N; Okunishi H
Eur J Pharmacol; 2011 Jan; 650(1):424-30. PubMed ID: 21034736
[TBL] [Abstract][Full Text] [Related]
8. [Antioxidative effects of cysteinyl leukotriene receptor antagonists montelukast and HAMI 3379 on ischemic injury in rat cortical neurons in vitro].
Xu DM; Zhang XY; Wang XR; Chen L; Zhang LH; Shi QJ; Fang SH; Lu YB; Zhang WP; Wei EQ
Zhejiang Da Xue Xue Bao Yi Xue Ban; 2014 May; 43(3):257-64. PubMed ID: 24998647
[TBL] [Abstract][Full Text] [Related]
9. Temporal profile of matrix metalloproteinases and their inhibitors in a human endothelial cell culture model of cerebral ischemia.
Reuter B; Rodemer C; Grudzenski S; Couraud PO; Weksler B; Romero IA; Meairs S; Bugert P; Hennerici MG; Fatar M
Cerebrovasc Dis; 2013; 35(6):514-20. PubMed ID: 23817219
[TBL] [Abstract][Full Text] [Related]
10. The Protective Effect of Safinamide in Ischemic Stroke Mice and a Brain Endothelial Cell Line.
Xu T; Sun R; Wei G; Kong S
Neurotox Res; 2020 Oct; 38(3):733-740. PubMed ID: 32613602
[TBL] [Abstract][Full Text] [Related]
11. Cysteinyl leukotriene receptor antagonist epigenetically modulates cytokine expression and maturation of human myeloid dendritic cells.
Kuo CH; Yang SN; Kuo HF; Lee MS; Huang MY; Huang SK; Lin YC; Hsieh CC; Hung CH
Pulm Pharmacol Ther; 2016 Aug; 39():28-37. PubMed ID: 27312202
[TBL] [Abstract][Full Text] [Related]
12. Montelukast targeting the cysteinyl leukotriene receptor 1 ameliorates Aβ1-42-induced memory impairment and neuroinflammatory and apoptotic responses in mice.
Lai J; Hu M; Wang H; Hu M; Long Y; Miao MX; Li JC; Wang XB; Kong LY; Hong H
Neuropharmacology; 2014 Apr; 79():707-14. PubMed ID: 24456746
[TBL] [Abstract][Full Text] [Related]
13. Cysteinyl leukotriene receptor antagonism: a promising pharmacological strategy for lowering the severity of arthritis.
Venugopal N; Acharya P; Zarei M; Talahalli RR
Inflammopharmacology; 2019 Oct; 27(5):923-931. PubMed ID: 31309487
[TBL] [Abstract][Full Text] [Related]
14. Montelukast rescues primary neurons against Aβ1-42-induced toxicity through inhibiting CysLT1R-mediated NF-κB signaling.
Lai J; Mei ZL; Wang H; Hu M; Long Y; Miao MX; Li N; Hong H
Neurochem Int; 2014 Sep; 75():26-31. PubMed ID: 24879954
[TBL] [Abstract][Full Text] [Related]
15. Effect of a cysteinyl leukotriene receptor antagonist on experimental emphysema and asthma combined with emphysema.
Ikeda G; Miyahara N; Koga H; Fuchimoto Y; Waseda K; Kurimoto E; Taniguchi A; Tanimoto Y; Kataoka M; Tanimoto M; Kanehiro A
Am J Respir Cell Mol Biol; 2014 Jan; 50(1):18-29. PubMed ID: 23937413
[TBL] [Abstract][Full Text] [Related]
16. Ang-(1-7) exerts protective role in blood-brain barrier damage by the balance of TIMP-1/MMP-9.
Wu J; Zhao D; Wu S; Wang D
Eur J Pharmacol; 2015 Feb; 748():30-6. PubMed ID: 25523481
[TBL] [Abstract][Full Text] [Related]
17. The anti-inflammatory effect of montelukast, a cysteinyl leukotriene receptor-1 antagonist, against estradiol-induced nonbacterial inflammation in the rat prostate.
Said MM; Bosland MC
Naunyn Schmiedebergs Arch Pharmacol; 2017 Feb; 390(2):197-205. PubMed ID: 27909742
[TBL] [Abstract][Full Text] [Related]
18. Montelukast attenuates interleukin IL-1β-induced oxidative stress and apoptosis in chondrocytes by inhibiting CYSLTR1 (Cysteinyl Leukotriene Receptor 1) and activating KLF2 (Kruppel Like Factor 2).
Li Z; Wang J; Ma Y
Bioengineered; 2021 Dec; 12(1):8476-8484. PubMed ID: 34565285
[TBL] [Abstract][Full Text] [Related]
19. Cysteinyl leukotriene receptor antagonist montelukast ameliorates acute lung injury following haemorrhagic shock in rats.
Al-Amran FG; Hadi NR; Hashim AM
Eur J Cardiothorac Surg; 2013 Feb; 43(2):421-7. PubMed ID: 22851661
[TBL] [Abstract][Full Text] [Related]
20. Zafirlukast protects blood-brain barrier integrity from ischemic brain injury.
Zeng C; Wang D; Chen C; Chen L; Chen B; Li L; Chen M; Xing H
Chem Biol Interact; 2020 Jan; 316():108915. PubMed ID: 31816286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
